UnitedHealth Update ‘not The End’ For Myriad’s GeneSight, Says Raymond James
The setback to the study is unlikely to have an impact on genesight selling prices or volumes, but myriad’s decision to disclose the news in a regulatory filing “is likely to raise. 1, 2024, 10:15 am. Stephens analyst mason carrico notes that myriad genetics (mygn) shares are down about 20% this morning, which the firm blames on an. Myriad genetics (nasdaq:mygn) is down ~20%in friday trading following reports that unitedhealth group (unh) will no longer cover the company's genetic test that. The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after genesight testing:
Unitedhealth will cover genetic testing using genesight in patients with major depressive disorder or anxiety whose condition previously worsened while taking one prior. Unitedhealthcare’s decision this month to cover genetic tests designed to predict a patient’s response to mental health medications has injected a dose of optimism for the.